Ceftazidime± avibactam with fosfomycin

Phase 3Small molecule

Ceftazidime± avibactam with fosfomycin is one of 8 small molecule programs targeting Gram-Negative Bacterial Infections. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gram-Negative Bacterial InfectionsRecruiting

Gram-Negative Bacterial InfectionsPhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Gram-Negative Bacterial Infections

#DrugCompanyPhaseTrials

Fetroja

Shionogi

Approved

1 2

Merrem

BB. Braun Medical Inc.

Approved

—3

Tygacil

PPrism Pharmaceuticals

Approved

—4

Avycaz

PPhiladelphia Eye Associates

Approved

—5

Ceftazidime± avibactam with fosfomycin

AAngela HUTTNER

Phase 3

1 6

Primaxin

ATM-AVI

1 8

Minocin

TTriax

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Gram-Negative Bacterial Infections

NCT07063095

Clinical

Trials by Indication[1]

Gram-Negative Bacterial Infections1 trial

A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections

Recruiting·AAngela HUTTNER·Phase 3·NCT07063095·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ceftazidime± avibactam with fosfomycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ceftazidime± avibactam with fosfomycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ceftazidime± avibactam with fosfomycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Angela HUTTNER company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAngela HUTTNER

Ceftazidime± avibactam with fosfomycin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Gram-Negative Bacterial Infections1 trial

References

Drug Info

Quick Facts

Related News